This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Prescribing Information for the United Kingdom click here.
An older adult RSV vaccination programme using ABRYSVO was introduced across the UK in 2024.² Following advice from the Joint Committee on Vaccination and Immunisation (JCVI), eligibility has expanded to include three adult populations.3
Adults aged 65-74 years are eligible if they have:4
3 minute video from global experts explaining the burden of RSV disease compared to influenza and the impact it has on older adults and the healthcare system.
Each year, RSV is estimated to lead to around 120,000 GP consultations, 13,000 hospitalisations, and 13,000 A&E attendances* for adults 75 years and older in the UK.**8
Hospital admission estimates were nearly 3 times higher† in adults ≥85 years compared to those 75-84 years old in England between October 2018 and April 2023.9
*Only includes A&E attendances that did not result in hospitalisation. **Data published in 2025. †587 admissions per 100,000 per year compared to 221 admissions per 100,000 per year.
Although it gets less attention than influenza, RSV is highly contagious and can be spread by asymptomatic carriers.11-13 Learn more about long RSV transmission and incubation periods and how symptoms can vary widely and are more severe at the extremes of age.11-16
In this video Rebecca shares her experience of RSV infection, including her symptoms, hospitalisation and the importance of being aware of RSV within the broader context of respiratory illnesses.
The safety profile of administering a single dose of ABRYSVO to individuals 18 years and older (n=20,275) was evaluated in clinical trials.1
The majority of reactions in individuals 18 years of age and older were mild to moderate in severity and resolved within 1-2 days of onset.1
The most frequently reported adverse reactions were fatigue (23%), headache (20%), vaccination site pain (19%) and myalgia (16%).1
| System organ class | Very common (≥1/10) | Common (≥1/100 to <1/10) | Uncommon (≥1/1000 to <1/100) | Rare (≥1/10,000 to <1/1000) | Very Rare (<1/10,000) | Not known (cannot be estimated from the available data) |
|---|---|---|---|---|---|---|
| Blood and lymphatic system disorders | - | - | - | Lymphadenopathy | - | - |
| Immune system disorders | - | - | - | Hypersensitivity reactions (includes rash, urticaria) | Anaphylaxis | - |
| Nervous system disorders | Headache | - | - | Guillain-Barré syndromea | - | - |
| Musculoskeletal and connective tissues disorders | Myalgia | Arthralgia | - | - | - | - |
| General disorders and administration site conditions | Fatigue, Vaccination site pain | Vaccination site redness, Vaccination site swelling | Pyrexia | Vaccination site pruritus, Vaccination site bruising, Vaccination site haematoma | - | - |
aFrequency reported in individuals 60 years of age and older
Among immunocompromised individuals 18 years of age and older, reactogenicity was consistent with the known profile of ABRYSVO. There were no unexpected safety findings.1
Please refer to the SmPC for additional safety information.
Contraindications1
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 of the SmPC.
| Special warning1 | Precaution for use1 |
|---|---|
| Traceability | In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. |
| Hypersensitivity and anaphylaxis | Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. |
| Anxiety-related reactions | Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from fainting. |
| Concurrent illness | Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination. |
| Thrombocytopenia and coagulation disorders | ABRYSVO should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding or bruising may occur following an intramuscular administration to these individuals. |
| Immunocompromised individuals | Safety and immunogenicity have been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of ABRYSVO may be lower in immunosuppressed individuals. |
| Guillain-Barré syndrome | Guillain-Barré syndrome has been reported rarely following vaccination with ABRYSVO in individuals ≥60 years1. The ABRYSVO patient information leaflet describes Guillain-Barré syndrome as a serious nerve condition that usually starts with pins and needles (an uncomfortable tingling sensation) and weakness of the legs and/or arms that can progress up to paralysis of part or all of the body, and include difficulty breathing. Urgent hospital treatment is required to help prevent the symptoms progressing and improve recovery, however the effects of Guillain-Barré syndrome may sometimes be long-lasting17. Healthcare professionals should be attentive to signs and symptons of Guillain-Barré syndrome in all ABRYSVO recipients to ensure correct diagnosis, in order to initiate adequate supportive care and treatment, and rule out other causes1. |
| Limitations of vaccine effectiveness | As with any vaccine, a protective immune response may not be elicited after vaccination. |
| Excipients | This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium‑free’. ABRYSVO contains polysorbate 80. Polysorbate 80 may cause hypersensitivity reactions. |
| Individuals less than 28 weeks gestation | ABRYSVO has not been studied in pregnant individuals less than 24 weeks of gestation and should not be used in pregnant individuals less than 28 weeks of gestation. |
This content is for the United Kingdom only. Please refer to the Summary of Product Characteristics for more information.
1. ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for the United Kingdom. Available at: https://www.medicines.org.uk/emc/product/15309.
2. UK Health Security Agency. RSV vaccination of older adults: information for healthcare practitioners. Updated June 2026. Available at: https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals/rsv-vaccination-of-older-adults-information-for-healthcare-practioners [Accessed August 2026]
3. UK Health Security Agency. RSV vaccination for older adults: expansion of eligibility. Annexe A: detailed information, guidance and resources for healthcare professionals. Published February 2026. Available at: https://www.gov.uk/government/publications/rsv-vaccination-for-older-adults-expansion-of-eligibility/annexe-a-detailed-information-guidance-and-resources-for-healthcare-professionals [Accessed August 2026]
4. UK Health Security Agency. Expansion of eligibility to adults aged 65 to 74 years in certain clinical at-risk groups letter. GOV.UK. Available at: https://www.gov.uk/government/publications/rsv-vaccination-expansion-of-eligibility-to-older-adults-in-certain-clinical-risk-groups/expansion-of-eligibility-to-adults-aged-65-to-74-years-in-certain-clinical-at-risk-groups-letter [Accessed August 2026]
5. Fleming DM, et al. BMC Infect Dis. 2015;15:443–455.
6. Stephens LM, Varga SM. Vaccines (Basel) 2021;9(6):624.
7. UK Department of Health and Social Care. Respiratory syncytial virus (RSV) immunisation programme for adults aged 80 years and older: JCVI advice, 16 July 2025. Available at: https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-16-july-2025/respiratory-syncytial-virus-rsv-immunisation-programme-for-adults-aged-80-years-and-older-jcvi-advice-16-july-2025 [Accessed August 2026].
8. Vyse A, et al. Journal of Pharmaceutical Policy and Practice. 2025; 18:1, 2576618.
9. Johannesen, C. et al. The Lancet Regional Health – Europe. 2025; 51, 101227.
10. UK Health Security Agency. Expansion of RSV vaccine eligibility to those aged 80 years and older and residents in care homes for older adults letter. Available at: https://www.gov.uk/government/publications/rsv-vaccination-for-older-adults-expansion-of-eligibility/expansion-of-rsv-vaccine-eligibility-to-those-aged-80-years-and-older-and-residents-in-care-homes-for-older-adults-letter. [Accessed August 2026].
11. Centres for Disease Control and Prevention. How RSV Spreads. Available at: https://www.cdc.gov/rsv/causes/index.html. [Accessed August 2026].
12. Carvajal JJ, et al. Front Immunol. 2019;10(2152):1-19.
13. Hall CB. Clin Infect Dis. 2000;31(2):590-596.
14. Eiland LS. J Pediatr Pharmacol Ther. 2009;14(2):75-85.
15. Talbot HK, et al. Infect Dis Clin Pract. 2016;24(6):295-302.
16. Centres for Disease Control and Prevention. RSV in older adults. https://www.cdc.gov/rsv/older-adults/index.html/ [Accessed August 2026].
17. ABRYSVO Patient Information Leaflet. Available at: www.medicines.org.uk/emc/product/15309/pil. [Accessed August 2026].
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025